jnj-69086420
mAbexperimentalADC
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 12, 2020 (NCT04644770)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Kallikrein 2INHIBITOR
KLK2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- 225-Actinium
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04644770 | Phase 1 | Nov 12, 2020 | Janssen Pharmaceutica NV |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | For profit | 1 | 1 | 1 | 2020 |
1 organizations
Page 1 / 1